TY - JOUR
T1 - Models of cardiac hypertrophy and transition to heart failure
AU - Berry, Jeff M.
AU - Naseem, R. Haris
AU - Rothermel, Beverly A
AU - Hill, Joseph A
N1 - Funding Information:
This work was supported by grants from the Donald W. Reynolds Cardiovascular Clinical Research Center, NIH (HL-075173, HL-006296, HL-080144, HL-072016) and AHA (0640084N, 0655202Y).
PY - 2007/12
Y1 - 2007/12
N2 - The prevalence of heart failure is increasing rapidly worldwide, and yet effective treatments remain elusive. Pathological remodeling of the ventricle - and associated hypertrophic growth, fibrotic change, cavity dilatation and electrophysiological remodeling - is a significant contributor to the pathogenesis of this prevalent disorder. As a consequence, there is great interest in developing new therapies to target pathological remodeling of the heart with the intent to prevent, arrest, or possibly reverse the otherwise inexorable progression of disease. To tackle this problem, numerous models of disease have been developed, both in vivo and in vitro. Here, we review models of cardiac hypertrophy and failure, compare and contrast their strengths and limitations, and on occasion cite recent works where the use of these models has contributed to significant scientific advances.
AB - The prevalence of heart failure is increasing rapidly worldwide, and yet effective treatments remain elusive. Pathological remodeling of the ventricle - and associated hypertrophic growth, fibrotic change, cavity dilatation and electrophysiological remodeling - is a significant contributor to the pathogenesis of this prevalent disorder. As a consequence, there is great interest in developing new therapies to target pathological remodeling of the heart with the intent to prevent, arrest, or possibly reverse the otherwise inexorable progression of disease. To tackle this problem, numerous models of disease have been developed, both in vivo and in vitro. Here, we review models of cardiac hypertrophy and failure, compare and contrast their strengths and limitations, and on occasion cite recent works where the use of these models has contributed to significant scientific advances.
UR - http://www.scopus.com/inward/record.url?scp=46749105977&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46749105977&partnerID=8YFLogxK
U2 - 10.1016/j.ddmod.2007.06.003
DO - 10.1016/j.ddmod.2007.06.003
M3 - Review article
AN - SCOPUS:46749105977
SN - 1740-6757
VL - 4
SP - 197
EP - 206
JO - Drug Discovery Today: Disease Models
JF - Drug Discovery Today: Disease Models
IS - 4
ER -